Newer Blood Thinner May Pose Danger to Trauma Patients
Pradaxa has caused severe bleeding problems that can't be reversed, trauma surgeon says
By Amanda Gardner
WEDNESDAY, Nov. 23 (HealthDay News) -- A new blood thinner touted for its convenience and enhanced quality of life may have hidden problems that could threaten the lives of certain patients, a new report suggests.
A letter to the editor in the Nov. 24 issue of the New England Journal of Medicine reports severe bleeding complications among trauma patients on the anti-clotting medicine Pradaxa (dabigatran etexilate).
In one case, a patient died, the letter said.
"We have noted on multiple occasions patients who have 'bleeding out' from Pradaxa and our hands are tied," said Dr. Bryan Cotton, lead letter author and a trauma surgeon with the University of Texas Health Science Center at Memorial Hermann Hospital in Houston. "They're bleeding out all over and there's absolutely nothing we can do about it . . . I'm helpless and hopeless when it comes into my emergency room."
The main problem, Cotton said, is that there's no real way to reverse the anti-clotting effect of the drug, unlike older agents such as warfarin.
According to the letter, the only way to reverse Pradaxa is with emergency dialysis but, said Cotton, "in a patient bleeding to death, that's not really a practical or pragmatic option."
Warfarin (Coumadin, Jantoven) has been the mainstay of blood-thinning medications to manage heart and stroke patients for decades.
But the drug is notoriously difficult to manage, requiring frequent lab tests and having interactions with multiple foods and other medications. Its one big advantage, however, is that its blood-thinning properties are easily reversible when needed.
Enter the new, easier-to-use blood thinner, Pradaxa, first approved by the U.S. Food and Drug Administration in late 2010 for use in patients with atrial fibrillation, a common and dangerous form of irregular heartbeat.
"There is an advantage over warfarin in many ways because of the simplicity and ease of management," said Dr. Jack Ansell, chairman of the department of medicine at Lenox Hill Hospital in New York City. "There are very little interactions with other drugs or foods, but once again, warfarin is relatively easily reversible."
Pradaxa also has other problems in addition to the irreversibility, the letter said, namely that there are no readily available tests to assess how well it's working or not working.
"You can't really check the labs. There's no easy, cheap, readily available lab test," Cotton noted.
The information provided in the letter, said Dr. Lisandro Irizarry, chair of emergency medicine at the Brooklyn Hospital Center in New York City, is "incredibly useful and incredibly timely."
"Although this medication provides enhanced quality of life, it does have a significant impact on how we manage patients because there's no way to reverse it and no way to measure how thin the blood is," he said.
Cotton and his co-authors urged the U.S. Food and Drug Administration (FDA) to support more trials to assess the potentially wide-ranging effects of the drug.
"We absolutely understand that it's a lot better for patients from a convenience standpoint . . . but when something goes wrong, it can go wrong very badly," Cotton said.
In a statement, Pradaxa's maker, Boehringer Ingelheim, confirmed that, "At this time, there is no reversal agent available" for the blood thinner. The company says that dialysis can lead to "the removal of about 60 percent of the drug over two to three hours; however, data supporting this approach are limited."
In the meantime, "Patient safety is our top priority and we frequently communicate with the FDA and regulatory agencies around the world to ensure they have the most up-to-date information regarding the safety profile of Pradaxa," the company said. "All treatment decisions should be made on an individual basis between patients and their health care providers and should take into consideration the overall benefits and risks associated with various treatment options."
Pradaxa is not the only new-generation blood thinner to be approved recently -- the anti-clotting drug Brilinta (ticagrelor) gained FDA approval for use in heart patients in July. However, according to Ansell, there is no "reversability" problem with Brilinta.
The U.S. National Library of Medicine has more on blood thinners.SOURCES: Bryan Cotton, M.D., trauma surgeon and intensivist, Memorial Hermann Hospital and University of Texas Health Science Center, Houston; Lisandro Irizarry, M.D., chair of emergency medicine, Brooklyn Hospital Center, New York City; Jack Ansell, M.D., chairman, department of medicine, Lenox Hill Hospital, New York City; Nov. 23, 2011, statement, Boehringer Ingelheim US, Ridgefield, Conn.; Nov. 24, 2011, New England Journal of Medicine Related Articles
- Special Ambulance Delivers Vital Stroke Care More Quickly
November 21, 2014
- Oxygen May Not Help Heart Attack Victims
November 19, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.